Morgan Stanley Boosts UiPath (NYSE:PATH) Price Target to $16.00

UiPath (NYSE:PATH – Get Rating) had its price objective lifted by Morgan Stanley from $15.00 to $16.00 in a research note issued to investors on Thursday, Benzinga reports. They currently have an equal weight rating on the healthcare company’s stock.

Several other research analysts also recently commented on the stock. Evercore ISI decreased their target price on shares of UiPath to $17.00 in a research note on Friday, December 2nd. Truist Financial reduced their price objective on shares of UiPath from $25.00 to $20.00 and set a buy rating on the stock in a research report on Friday, December 2nd. Canaccord Genuity Group raised shares of UiPath from a hold rating to a buy rating and boosted their price objective for the company from $14.50 to $19.00 in a research report on Thursday. Wells Fargo & Company boosted their price objective on shares of UiPath from $16.00 to $18.00 and gave the company an overweight rating in a research report on Friday, December 2nd. Finally, Barclays upped their target price on shares of UiPath from $13.00 to $17.00 and gave the stock an equal weight rating in a research report on Thursday. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Hold and an average target price of $19.19.

UiPath Stock Performance

Shares of PATH opened at $17.05 on Thursday. The firm has a market cap of $9.43 billion, a price-to-earnings ratio of -28.42 and a beta of 0.60. UiPath has a fifty-two week low of $10.40 and a fifty-two week high of $31.88. The firm has a 50 day moving average price of $15.06 and a 200-day moving average price of $13.60.

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 40,000 shares of the stock in a transaction that occurred on Wednesday, February 15th. The shares were sold at an average price of $16.61, for a total value of $664,400.00. Following the transaction, the chief financial officer now owns 1,359,051 shares in the company, valued at approximately $22,573,837.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 31.88% of the company’s stock.

Hedge Funds Weigh In On UiPath

Institutional investors have recently made changes to their positions in the business. Guggenheim Capital LLC lifted its stake in shares of UiPath by 18.8% in the 3rd quarter. Guggenheim Capital LLC now owns 63,663 shares of the healthcare company’s stock worth $803,000 after purchasing an additional 10,062 shares during the period. Alps Advisors Inc. bought a new stake in UiPath in the second quarter worth $2,145,000. B. Metzler seel. Sohn & Co. AG bought a new stake in UiPath in the second quarter worth $226,000. Interchange Capital Partners LLC lifted its position in UiPath by 7.9% in the third quarter. Interchange Capital Partners LLC now owns 17,212 shares of the healthcare company’s stock worth $217,000 after buying an additional 1,256 shares during the last quarter. Finally, Archford Capital Strategies LLC lifted its position in UiPath by 58.2% in the third quarter. Archford Capital Strategies LLC now owns 22,520 shares of the healthcare company’s stock worth $284,000 after buying an additional 8,283 shares during the last quarter. Institutional investors own 56.40% of the company’s stock.

About UiPath

(Get Rating)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.